IADVL SIG Recalcitrant Dermatophytosis Position Statement on Super Bioavailable Itraconazole

8Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Abstract: Itraconazole (ITZ) has been the mainstay of oral antifungal treatment for the current epidemic of recalcitrant dermatophytosis (RD) in India. Recently, a newer formulation of ITZ, super bioavailable itraconazole (SUBA-ITZ), is made available in the market by many pharmaceutical companies. It is important for dermatologists to understand the pharmacokinetic properties of SUBA-ITZ vis-a-vis conventional pellet formulation to use it effectively and safely. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) has established a special interest group for recalcitrant dermatophytosis (SIG-RD) to strengthen research, continuing medical education, and industry collaboration on the subject. This position statement on SUBA-ITZ by SIG-RD is an attempt to address current pieces of evidence and the position of this new formulation in the management of RD.

Cite

CITATION STYLE

APA

Patel, N. H., Sardana, K., Shenoy, M. M., Rengasamy, M., Khurana, A., Ghate, S., … Jain, A. K. (2024). IADVL SIG Recalcitrant Dermatophytosis Position Statement on Super Bioavailable Itraconazole. Indian Dermatology Online Journal, 15(1), 1–7. https://doi.org/10.4103/idoj.idoj_668_22

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free